JP2010510238A - γ線被曝に対する放射線防護および治療の方法 - Google Patents

γ線被曝に対する放射線防護および治療の方法 Download PDF

Info

Publication number
JP2010510238A
JP2010510238A JP2009537375A JP2009537375A JP2010510238A JP 2010510238 A JP2010510238 A JP 2010510238A JP 2009537375 A JP2009537375 A JP 2009537375A JP 2009537375 A JP2009537375 A JP 2009537375A JP 2010510238 A JP2010510238 A JP 2010510238A
Authority
JP
Japan
Prior art keywords
alkyl
branched
linear
lpa
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009537375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510238A5 (https=
Inventor
ウェンリン デング
ベーリサ グドゥドゥル
ガンガドハー ダーガム
ガボア ティジー
デュエイン ミラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of JP2010510238A publication Critical patent/JP2010510238A/ja
Publication of JP2010510238A5 publication Critical patent/JP2010510238A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009537375A 2006-11-15 2007-11-15 γ線被曝に対する放射線防護および治療の方法 Pending JP2010510238A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86587106P 2006-11-15 2006-11-15
PCT/US2007/084875 WO2008140574A2 (en) 2006-11-15 2007-11-15 Radiation protection and treatment for exposure to gamma-radiation

Publications (2)

Publication Number Publication Date
JP2010510238A true JP2010510238A (ja) 2010-04-02
JP2010510238A5 JP2010510238A5 (https=) 2011-01-06

Family

ID=40002804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537375A Pending JP2010510238A (ja) 2006-11-15 2007-11-15 γ線被曝に対する放射線防護および治療の方法

Country Status (6)

Country Link
EP (1) EP2099469A4 (https=)
JP (1) JP2010510238A (https=)
AU (1) AU2007353320B2 (https=)
CA (1) CA2705612A1 (https=)
IL (1) IL198789A0 (https=)
WO (1) WO2008140574A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018016523A1 (ja) * 2016-07-20 2018-01-25 国立大学法人 長崎大学 新規放射線防護剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935677C (en) * 2013-12-30 2022-07-26 Rama Krishna Reddy SINGIDI Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate
WO2017011457A1 (en) * 2015-07-12 2017-01-19 The University Of Tennessee Research Foundation Compositions and methods for protecting colonic epithelial barrier function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032494A2 (en) * 2003-10-09 2005-04-14 University Of Tennessee Research Foundation Lpa receptor agonists and antagonists and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078111A1 (en) * 2005-07-19 2007-04-05 Gabor Tigyi LPA2 receptor agonist inhibitors of CFTR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032494A2 (en) * 2003-10-09 2005-04-14 University Of Tennessee Research Foundation Lpa receptor agonists and antagonists and methods of use

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6012056407; ＤＥＮＧ，Ｗ．　ｅｔ　ａｌ: 'Ｌｙｓｏｐｈｏｓｐｈａｔｉｄｉｃ　ａｃｉｄ　ｐｒｏｔｅｃｔｓ　ａｎｄ　ｒｅｓｃｕｅｓ　ｉｎｔｅｓｔｉｎａｌ　ｅｐｉｔｈｅｌｉａｌ　ｃｅｌｌｓ　ｆｒｏｍ　ｒａｄｉａｔｉｏｎ-　ａｎｄ　ｃｈｅｍｏｔｈｅｒ' Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ Ｖｏｌ．１２３，　Ｎｏ．１, 2002, ｐ．２０６-１６ *
JPN6012056410; 産科と婦人科 Ｖｏｌ．４７，Ｎｏ．４, 1980, ｐ．７０４-７０６ *
JPN6013029603; メルクマニュアル第１７版日本語版 , 1999, ｐ．２４３７-２４４１ *
JPN6013029607; ＣＵＩ，Ｙ．Ｆ．　ｅｔ　ａｌ: 'Ａｐｏｐｔｏｓｉｓ　ｏｆ　ｃｉｒｃｕｌａｔｉｎｇ　ｌｙｍｐｈｏｃｙｔｅｓ　ｉｎｄｕｃｅｄ　ｂｙ　ｗｈｏｌｅ　ｂｏｄｙ　ｇａｍｍａ-ｉｒｒａｄｉａｔｉｏｎ　ａｎｄ　ｉｔｓ　ｍｅｃｈａｎｉｓｍ' Ｊ　Ｅｎｖｉｒｏｎ　Ｐａｔｈｏｌ　Ｔｏｘｉｃｏｌ　Ｏｎｃｏｌ Ｖｏｌ．１８，　Ｎｏ．３, 1999, ｐ．１８５-９ *
JPN7012004419; ＤＥＮＧ，Ｗ．　ｅｔ　ａｌ: 'ＬＰＡ　ｐｒｏｔｅｃｔｓ　ｉｎｔｅｓｔｉｎａｌ　ｅｐｉｔｈｅｌｉａｌ　ｃｅｌｌｓ　ｆｒｏｍ　ａｐｏｐｔｏｓｉｓ　ｂｙ　ｉｎｈｉｂｉｔｉｎｇ　ｔｈｅ　ｍｉｔｏｃｈｏｎｄｒｉａｌ　ｐａｔｈｗａｙ' Ａｍ　Ｊ　Ｐｈｙｓｉｏｌ　Ｇａｓｔｒｏｉｎｔｅｓｔ　Ｌｉｖｅｒ　Ｐｈｙｓｉｏｌ Ｖｏｌ．２８４，　Ｎｏ．５, 2003, ｐ．Ｇ８２１-９ *
JPN7013002285; ＧＯＥＴＺＬ，Ｅ．Ｊ．　ｅｔ　ａｌ: 'Ｌｙｓｏｐｈｏｓｐｈａｔｉｄｉｃ　ａｃｉｄ　ａｎｄ　ｓｐｈｉｎｇｏｓｉｎｅ　１-ｐｈｏｓｐｈａｔｅ　ｐｒｏｔｅｃｔｉｏｎ　ｏｆ　Ｔ　ｃｅｌｌｓ　ｆｒｏｍ　ａｐｏｐｔｏｓｉｓ　ｉｎ　ａｓｓｏｃｉａｔｉｏ' Ｊ　Ｉｍｍｕｎｏｌ Ｖｏｌ．１６２，　Ｎｏ．４, 1999, ｐ．２０４９-５６ *
JPN7013002286; ＨＵ，Ｘ．　ｅｔ　ａｌ: 'Ｌｙｓｏｐｈｏｓｐｈａｔｉｄｉｃ　ａｃｉｄ　（ＬＰＡ）　ｐｒｏｔｅｃｔｓ　ｐｒｉｍａｒｙ　ｃｈｒｏｎｉｃ　ｌｙｍｐｈｏｃｙｔｉｃ　ｌｅｕｋｅｍｉａ　ｃｅｌｌｓ　ｆｒｏｍ　ａｐｏｐｔｏｓｉｓ　ｔｈｒｏｕ' Ｊ　Ｂｉｏｌ　Ｃｈｅｍ Ｖｏｌ．２８０，　Ｎｏ．１０, 2005, ｐ．９４９８-５０８ *
JPN7013002287; ＰＲＺＥＭＥＣＫ，Ｓ．Ｍ．　ｅｔ　ａｌ: 'Ｒａｄｉａｔｉｏｎ-ｉｎｄｕｃｅｄ　ｇａｓｔｒｉｃ　ｅｐｉｔｈｅｌｉａｌ　ａｐｏｐｔｏｓｉｓ　ｏｃｃｕｒｓ　ｉｎ　ｔｈｅ　ｐｒｏｌｉｆｅｒａｔｉｖｅ　ｚｏｎｅ　ａｎｄ　ｉｓ　ｒｅｇｕｌａｔｅｄ　ｂｙ' Ａｍ　Ｊ　Ｐｈｙｓｉｏｌ　Ｇａｓｔｒｏｉｎｔｅｓｔ　Ｌｉｖｅｒ　Ｐｈｙｓｉｏｌ Ｖｏｌ．２９２，　Ｎｏ．２, 200610, ｐ．Ｇ６２０-７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018016523A1 (ja) * 2016-07-20 2018-01-25 国立大学法人 長崎大学 新規放射線防護剤

Also Published As

Publication number Publication date
IL198789A0 (en) 2011-08-01
CA2705612A1 (en) 2008-11-20
AU2007353320B2 (en) 2014-01-23
EP2099469A4 (en) 2013-02-27
WO2008140574A3 (en) 2009-01-15
WO2008140574A2 (en) 2008-11-20
AU2007353320A1 (en) 2008-11-20
EP2099469A2 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
Deng et al. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury
Zadra et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis
US8288378B2 (en) Phosphoinositide modulation for the treatment of neurodegenerative diseases
M. Healy et al. Sphingosine-1-phosphate receptors in the central nervous and immune systems
Xia et al. Carnosic acid (CA) attenuates collagen-induced arthritis in db/db mice via inflammation suppression by regulating ROS-dependent p38 pathway
Ren et al. Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR
US20140011761A1 (en) Modulating Endoplasmic Reticulum Stress in the Treatment of Tuberous Sclerosis
US12458630B2 (en) Combination therapy for cancer
EP2637649A2 (en) Compounds and methods for treating pain
Fang et al. Puerarin induces macrophage M2 polarization to exert antinonalcoholic steatohepatitis pharmacological activity via the activation of autophagy
KR20110132446A (ko) 키나아제 단백질 결합 억제제
US20120028921A1 (en) Methods and compositions using oxidized phospholipids
US20240350481A1 (en) Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders
Konończuk et al. Cerulein-induced acute pancreatitis affects sphingomyelin signaling pathway in rats
Xu et al. Phosphoethanolamine cytidylyltransferase ameliorates mitochondrial function and apoptosis in hepatocytes in T2DM in vitro
Zhang et al. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1
CN110869026A (zh) 降低心脏毒性的组合物和方法
Sharma et al. Targeting oligodendrocyte dynamics and remyelination: emerging therapies and personalized approaches in multiple sclerosis management
AU2007353320B2 (en) Radiation protection and treatment for exposure to gamma-radiation
Walter et al. Pharmacological inhibition of acid sphingomyelinase ameliorates experimental autoimmune encephalomyelitis
KR20220035275A (ko) 다발성 골수종 치료
CA3180522A1 (en) Therapeutic methods for preventing tumor metastasis and tumor recurrence
Xu et al. Evaluation of the protective effect of compound kushen injection against radiation-induced pneumonitis in mice
US11137400B2 (en) Methods for predicting and determining responsiveness to activators of JNK kinase
Hu et al. AMPK acts to remove immune barriers to CD8+ T cell-mediated immunity against hepatocellular carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131128